XORTX Therapeutics has enhanced its biopharmaceutical pipeline by adding a late-stage gout treatment and advancing renal anti-fibrotic programs through acquisitions. The company maintains strong liquidity but operates with losses typical of early-stage biotech investing heavily in R&D. Critical milestones ahead include the completion of the Vectus Biosystems acquisition and progress toward NDA review for XORLO. Regulatory approvals remain the predominant risk to commercial success as XORTX navigates clinical development and capital market requirements.